<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00737776</url>
  </required_header>
  <id_info>
    <org_study_id>BIASP-3547</org_study_id>
    <nct_id>NCT00737776</nct_id>
  </id_info>
  <brief_title>Observational Study on Efficacy and Safety in Patients Using NovoMix® 30 for the Treatment of Diabetes</brief_title>
  <acronym>UPGRADE</acronym>
  <official_title>NovoMix® 30 UPGRADE (NovoMix® 30 Use for Progressed Glycemic Control in Realistic Administration to DiabEtes Mellitus): A Multicentre, Open Label, Nonrandomised, Non-interventional, Observational, Efficacy and Safety Study in Patients Using Biphasic Insulin Aspart 30 (NovoMix® 30) for the Treatment of Diabetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novo Nordisk A/S</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novo Nordisk A/S</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is conducted in Asia. The aim of this observational study is to evaluate the
      efficacy on blood glucose control while using NovoMix® 30 FlexPen® under normal clinical
      practice conditions in Korea. A clinical safety profile will be also evaluated.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2008</start_date>
  <completion_date type="Actual">January 2010</completion_date>
  <primary_completion_date type="Actual">January 2010</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>HbA1c change</measure>
    <time_frame>at the end of study after 26 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of serious adverse drug reactions</measure>
    <time_frame>during the study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of serious adverse events</measure>
    <time_frame>during the study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of all major (daytime and nocturnal) hypoglycaemic events</measure>
    <time_frame>during the study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of major hypoglycaemic events related to omission of a meal after NovoMix® 30 injection</measure>
    <time_frame>during the study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of major hypoglycaemic events related to physical exercise of at least 30 min</measure>
    <time_frame>during the study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of all minor (daytime and nocturnal) hypoglycaemic events</measure>
    <time_frame>during the study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Weight (BMI) change</measure>
    <time_frame>at the end of study after 26 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lipid profile (Total cholesterol, LDL, HDL, Triglyceride) change</measure>
    <time_frame>at the end of study after 26 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients reaching the target of HbA1c below or equal to 6.5%</measure>
    <time_frame>at the end of study after 26 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients reaching the target of HbA1c below or equal to 7.0%</measure>
    <time_frame>at the end of study after 26 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients reaching the physician's own target recommendation</measure>
    <time_frame>at the end of study after 26 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Variability in fasting plasma glucose values and average (mean) fasting plasma glucose level</measure>
    <time_frame>at the end of study after 26 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average post-breakfast (2h), post-lunch (2h), post-dinner (2h) plasma glucose level</measure>
    <time_frame>at the end of study after 26 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Diabetes Fear of Self-Injection Questionnaire (D-FISQ)</measure>
    <time_frame>at the end of study after 26 weeks</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">1068</enrollment>
  <condition>Diabetes</condition>
  <condition>Diabetes Mellitus, Type 1</condition>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>biphasic insulin aspart 30</intervention_name>
    <description>Dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation</description>
    <arm_group_label>A</arm_group_label>
    <other_name>NovoMix® 30</other_name>
    <other_name>NovoLog® Mix 70/30</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Any patient with type 1 and type 2 diabetes who are prescribed with NovoMix® 30
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Any patient with type 1 and type 2 diabetes who are treated with NovoMix® 30

          -  Patient who signed on informed consent form

        Exclusion Criteria:

          -  Patients who are unlikely to comply with protocol requirements, e.g., uncooperative
             attitude, inability to return for the final visit

          -  Patients who were previously enrolled in this study

          -  Patients with a hypersensitivity to NovoMix® 30 or to any of the excipients

          -  Women who are pregnant, breast feeding or have the intention of becoming pregnant
             within next 12 months
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Global Clinical Registry (GCR, 1452)</last_name>
    <role>Study Director</role>
    <affiliation>Novo Nordisk A/S</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Seoul</city>
        <zip>137-920</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <link>
    <url>http://novonordisk-trials.com</url>
    <description>Clinical Trials at Novo Nordisk</description>
  </link>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 19, 2008</study_first_submitted>
  <study_first_submitted_qc>August 19, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 20, 2008</study_first_posted>
  <last_update_submitted>October 27, 2016</last_update_submitted>
  <last_update_submitted_qc>October 27, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 31, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin aspart, insulin aspart protamine drug combination 30:70</mesh_term>
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Insulin Aspart</mesh_term>
    <mesh_term>Biphasic Insulins</mesh_term>
    <mesh_term>Insulin, Isophane</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

